Genomic Instability and Tumorigenesis are Long-Term Effects of Therapeutic CRISPR/Cas9 Genome Editing in Hereditary Tyrosinemia Type I

被引：0

作者：

Bissig, Karl-Dimiter ^{[1
]}

Furey, Nika ^{[1
]}

Chen, Tong ^{[1
]}

Kim, Hyunjae Ryan ^{[2
]}

Pankowicz, Francis ^{[2
]}

Barzi, Mercedes ^{[1
]}

Legras, Xavier ^{[1
]}

Martins, Celeste Santos ^{[2
]}

Elsea, Sarah ^{[3
]}

Hurley, Ayrea ^{[2
]}

Wheeler, David ^{[2
]}

Borowiak, Malgorzata ^{[2
]}

Bissig-Choisat, Beatrice ^{[1
]}

Lagor, William ^{[2
]}

Sumazin, Pavel ^{[2
]}

机构：

[1] Duke Univ, Durham, NC USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Baylor Coll Med, Houston, NC USA

来源：

MOLECULAR THERAPY | 2020年 / 28卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

961

引用

页码：419 / 420

页数：2

共 50 条

[11] Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders
Yan Chen
Ruiting Wen
Zhigang Yang
Zhanghui Chen
Gene Therapy, 2022, 29 : 207 - 216
[12] CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss
Rimsha Farooq
Khadim Hussain
Muhammad Tariq
Ali Farooq
Muhammad Mustafa
Journal of Applied Genetics, 2020, 61 : 51 - 65
[13] CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss
Farooq, Rimsha
Hussain, Khadim
Tariq, Muhammad
Farooq, Ali
Mustafa, Muhammad
JOURNAL OF APPLIED GENETICS, 2020, 61 (01) : 51 - 65
[14] Intravenous and intranasal genome editing using the CRISPR/Cas9 system leads to long-term improvements in MPS I mice
Schuh, Roselena S.
Poletto, Edina
Rodrigues, Graziella
Vieira, Camila
Meyer, Fabiola S.
Giugliani, Roberto
Matte, Ursula
Teixeira, Helder F.
Baldo, Guilherme
MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S126 - S126
[15] Generation of genomic structural variants by CRISPR/Cas9 genome editing in rodents
Birling, Marie-Christine
Schaeffer, Laurence
Andre, Philippe
Pavlovic, Guillaume
Herault, Yann
TRANSGENIC RESEARCH, 2016, 25 (02) : 213 - 214
[16] Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing
Duan, Li
Ouyang, Kan
Wang, Jianhong
Xu, Limei
Xu, Xiao
Wen, Caining
Xie, Yixin
Liang, Yujie
Xia, Jiang
CHEMBIOCHEM, 2021, 22 (24) : 3360 - 3368
[17] CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications
Cheng, Hao
Zhang, Feng
Ding, Yang
PHARMACEUTICS, 2021, 13 (10)
[18] In Vivo Genome Editing in Type I and II Methanotrophs Using a CRISPR/Cas9 System
Rumah, Bashir L.
Stevens, Benedict H. Claxton
Yeboah, Jake E.
Stead, Christopher E.
Harding, Emily L.
Minton, Nigel P.
Zhang, Ying
ACS SYNTHETIC BIOLOGY, 2023, 12 (02): : 544 - 554
[19] Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease
Park, So Hyun
Lee, Ciaran M.
Deshmukh, Harshavardhan
Bao, Gang
BLOOD, 2016, 128 (22)
[20] Genome editing in mucopolysaccharidosis type IVA fibroblasts using CRISPR/Cas9
Suarez, Diego A.
Almeciga, Carlos J.
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S117 - S117

← 1 2 3 4 5 →